Heyholder
‹ Activism FilingsMajor

BUKWANG PHARMACEUTICAL IND CO.,LTD Q3 revenue KRW 56.1 billion, operating profit KRW 1.7 billion

BUKWANG PHARMACEUTICAL IND CO.,LTD· Periodic Report

AI summary · Not investment advice

Bukwang Pharmaceutical sold KRW 56.1 billion in Q3 and earned KRW 1.7 billion from its main business, up 76.4% from a year earlier and 22.5% from the prior quarter.

Operating profit · 3 months

KRW 1.7 billion

Key facts

Revenue (3 months)
KRW 56.1 billion
Net income (3 months)
KRW 338.8 million
Period
Q3 (cumulative 2026.01.01 ~ 2026.09.30)
Revenue (prior-year 3 months)
KRW 47.8 billion
Revenue (year to date)
KRW 160.8 billion
Operating profit (prior-year 3 months)
KRW 979.1 million
Operating profit (year to date)
KRW 4.2 billion
Net income (prior-year 3 months)
KRW 1.5 billion
Net income (year to date)
KRW 2.9 billion

Commentary

AI commentary · Not investment advice

What happened

Bukwang Pharmaceutical filed its quarterly report with consolidated results for the third quarter of 2026.

In the company's terms

Sales for the 3 months were KRW 56.07 billion. That is 17.3% above the same 3 months a year earlier, and 1.6% below the previous quarter. Cumulative sales this year are KRW 160.83 billion.

What changes for shareholders

Operating profit (profit from the core business) for the 3 months was KRW 1.73 billion. That is 76.4% above a year earlier and 22.5% above the previous quarter. Cumulative operating profit this year is KRW 4.24 billion.

Net income (the final profit after taxes and other costs) for the 3 months was KRW 0.34 billion. That is 77.4% below a year earlier and 75.6% below the previous quarter. Cumulative net income this year is KRW 2.89 billion.

Comments

No comments yet

Comments from shareholders will appear here.